The Technical Analyst
Magenta Therapeutics Inc [MGTA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Magenta Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.74% $0.700
America/New_York / 11 sep 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 42.44 mill |
| EPS: | -1.150 |
| P/E: | -0.608 |
| Earnings Date: | Nov 01, 2023 |
| SharesOutstanding: | 60.66 mill |
| Avg Daily Volume: | 0.248 mill |
| RATING 2023-09-11 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.608 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.608 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.664 - 0.736 ( +/- 5.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-29 | Fairmount Funds Management Llc | Buy | 24 670 | Common Stock |
| 2023-09-26 | Fairmount Funds Management Llc | Buy | 30 000 | Common Stock |
| 2023-09-22 | Randhawa Simrat | Buy | 2 000 | Common Stock |
| 2023-09-21 | Randhawa Simrat | Buy | 2 000 | Common Stock |
| 2023-09-19 | Fairmount Funds Management Llc | Buy | 30 000 | Common Stock |
| INSIDER POWER |
|---|
| -68.02 |
| Last 94 transactions |
| Buy: 3 902 024 | Sell: 4 691 992 |
Forecast:
01:40 - $0.785
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.700 (-7.74% ) |
| Volume | 0.376 mill |
| Avg. Vol. | 0.248 mill |
| % of Avg. Vol | 151.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MGTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MGTA
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2023-09-11 11:33:00 - Press Release
Magenta Therapeutics Announces Completion Of Merger With Dianthus Therapeutics And Implementation Of Reverse Stock Split
The combined company will operate as “dianthus therapeutics, inc.” with its common stock traded on nasdaq under trading symbol “dnth” effective tuesday, september 12, 2023 the combined company will operate as “dianthus therapeutics, inc.” with its common stock traded on nasdaq under trading symbol “dnth” effective tuesday, september 12, 2023
2023-08-07 16:03:00 - Press Release
Magenta Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Magenta Therapeutics, Inc. - Mgta
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of magenta therapeutics, inc. (nasdaqgm: mgta) with dianthus therapeutics, inc. pursuant to which magenta shareholders are expected to own approximately 21.3% of the combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues th.
2022-12-12 08:00:00 - Press Release
Magenta Therapeutics To Host Conference Call And Webcast On Tuesday, December 13, 2022, To Review Mgta-117 Clinical Data From Ongoing Phase 1/2 Clinical Trial
Cambridge, mass., dec. 12, 2022 (globe newswire) -- magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. eastern time (et) / 7:30 a.m. central time (ct) tomorrow, tuesday, december 13, 2022 to review the mgta-117 clinical data from its ongoing phase 1/2 does escalation clinical trial that will be presented at the 2022 american society of hematology (ash) annual meeting.
2021-08-03 17:30:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Magenta Therapeutics, Inc. - Mgta
New york, aug. 3, 2021 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of magenta therapeutics, inc. ("magenta" or the "company") (nasdaq: mgta). such investors are advised to contact robert s.
2021-08-01 11:50:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Magenta Therapeutics, Inc. - Mgta
New york, new york--(newsfile corp. - august 1, 2021) - pomerantz llp is investigating claims on behalf of investors of magenta therapeutics, inc. ("magenta" or the "company") (nasdaq: mgta). such investors are advised to contact robert s. willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.the investigation concerns whether magenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [click here for information about joining...
Latest News
2023-04-03 22:49:50 - 24/7 Wall Street
10 Best-Performing Penny Stocks in the Health Care Sector
2023-03-30 09:54:48 - Zacks Investment Research
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).
2023-02-05 00:21:23 - Pulse2
MGTA Stock: 51.66% Surge Explained
The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.
2022-12-21 09:02:13 - Zacks Investment Research
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
2022-12-20 15:35:22 - Pulse2
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.
2022-12-12 08:00:00 - GlobeNewsWire
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
2022-05-16 11:17:26 - Zacks Investment Research
After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-04-14 12:23:03 - Benzinga
Magenta Therapeutics Trims R&D, Cuts Workforce
Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research.
2021-11-10 06:20:00 - The Motley Fool
Big Pharma Is Going Holiday Shopping. Who's Next?
After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
2021-09-19 06:06:41 - Seeking Alpha
Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge
Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative conditions above the 40 MG level.